The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index; 73 of the 169 sources its claims cite were checked for support.
Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement.
Open accessAbstract
Endogenous Cushing syndrome (CS) is a rare disorder resulting from chronic exposure to excessive concentrations of cortisol. It is likely underdiagnosed because many clinical signs and symptoms are non-specific and overlap with those of common conditions. Furthermore, biochemical testing to diagnose CS can be complex and challenging, especially in milder cases. CS is characterized by excessive daily cortisol production, but it is also associated with a disrupted circadian rhythm of cortisol secretion. Traditional cortisol monitoring techniques rely on single-time-point measurements or a cumulation of measurements, which are unable to capture the complete daily rhythm of cortisol fluctuations. Currently, the utility of assessing individual patients' cortisol circadian rhythm during diagnosis and treatment of CS is not well characterized. In this review, we will discuss how cortisol is measured in clinical practice and the potential benefit of measurement and normalization of the cortisol circadian rhythm.
Overview
CoChat Summary
## TL;DR
This review argues that Cushing syndrome is not just excess cortisol, but also a disorder of disrupted cortisol circadian rhythm, and that current single-time-point tests miss clinically important variability. It highlights emerging tools—especially multiple salivary measures, hair cortisol/cortisone, and continuous subcutaneous monitoring—as promising but not yet fully validated for routine use.
## Key findings
- Current standard screening tests for Cushing syndrome—24-hour urinary free cortisol (UFC), late-night salivary cortisol (LNSC), and the 1-mg dexamethasone suppression test (DST)—each have important limitations and can miss cyclical or mild disease because they sample cortisol at a single point or over a limited period.
- In the paper’s cited study of 12 patients with mild autonomous cortisol secretion (MACS) vs 10 referent subjects, 24-hour total/free cortisol levels were similar, but cortisol secretion differed significantly at 2200 and 0000 hours, showing that circadian disruption can exist despite normal integrated cortisol measures.
- Hair cortisol/cortisone studies report diagnostic cutoffs of about 5–31 pg/mg for hair cortisol and 14–28 pg/mg for hair cortisone, with sensitivities of approximately 60–100% and specificities of approximately 79–99%, but thresholds vary widely.
- Continuous subcutaneous cortisol monitoring has produced 72-hour profiles in 16 healthy men and 24-hour dynamic profiles in 214 healthy volunteers, but the devices are not yet approved for clinical use and remain research tools.
## Methods
- Narrative review of cortisol measurement in endogenous Cushing syndrome, covering diagnosis, monitoring, circadian rhythm assessment, and treatment response.
- Synthesizes evidence from screening-test guidance and multiple cited studies in patients with Cushing syndrome, MACS, and healthy controls, including studies using UFC, LNSC, DST, hair cortisol/cortisone, and continuous subcutaneous monitoring.
- Uses comparative interpretation of prior observational studies, prospective studies, phase 3 trial analyses, and case series to evaluate how well each cortisol measure reflects circadian rhythm and disease control.
## Limitations
- The paper itself states that the utility of assessing individual patients’ cortisol circadian rhythm during diagnosis and treatment is not well characterized, and that there is currently no guidance for monitoring treatment response with respect to restoration of cortisol circadian rhythm.
- It also states that continuous subcutaneous monitoring devices are not yet approved for clinical use, remain limited to research settings, and lack sufficient evidence for diagnostic purposes.
- Evident from the text: this is a review, so it does not present a single original patient cohort or one unified analytical dataset; conclusions depend on heterogeneous cited studies with varying assays, populations, and endpoints.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
38 Valid · 0 Not valid · 38 Not checked · 20 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These challenges often lead to delayed diagnosis, contributing to increased morbidity and mortality (48-50, 53).”
§ Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement > Diagnostic algorithm
What the sources say
- Not checked — no full text of the sourcecites [48] Ceccato, 2025, Clinical and biochemical data for the diagnosis of endogenous hypercortisolism: the “cushingomic” approach, J Clin Endocrinol Metab source
- Supportedcites [49] Braun, 2022, Whom should we screen for Cushing syndrome? The Endocrine Society practice guideline recommendations 2008 revisited, J Clin Endocrinol Metab source
The Abstract (page not specified in the supplied passage) says that low incidence and overlapping symptoms can delay diagnosis and treatment, resulting in increased morbidity and mortality. The Implications for Clinical Practice section likewise links late diagnosis with increased morbidity and mortality. (LLM, conf=0.94)
- Partly supportedcites [50] Rubinstein, 2020, Time to diagnosis in Cushing's syndrome: a meta-analysis based on 5367 patients, J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
The paper says that overlapping symptoms can delay CS diagnosis, and its Discussion reports a mean time to diagnosis of 34 months. It also says that the duration of hypercortisolism appears to be an important determinant of morbidity and premature mortality. However, it does not directly establish that the diagnostic delays it measured increased those outcomes; the claim presents that link more definitively than the paper does. (LLM, conf=0.82)
- Partly supportedcites [53] Ragnarsson, 2019, Overall and disease-specific mortality in patients with Cushing disease: a Swedish nationwide study, J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
Ragnarsson et al. (2019) clearly support the increased-morbidity/mortality half of the claim: the Abstract (Introduction) notes 50% of untreated CS patients died within 5 years of diagnosis and that mortality remains increased, particularly in patients not in remission, and the Conclusion (Discussion) states patients with CD continue to have excess mortality even after remission. However, the paper does not attribute this to diagnostic delay: the Discussion states that information on duration of active CS was not available, and that a related measure of untreated CS — time from diagnosis to curative treatment — was NOT associated with increased mortality risk (Cox model 1, HR 0.8, 95% CI 0.6–1.1, P = 0.16; Results, 'Influence of remission status...'). The only mention of duration of active disease as a mortality predictor is credited to a previous study (their reference 14), not to their own findings. Thus the causal link 'delayed diagnosis contributes to increased morbidity and mortality' is not what this source shows. (LLM, conf=0.75)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The loss of circadian rhythm with the absence of a late-night cortisol nadir is a hallmark biochemical abnormality in patients with CS (11, 25, 26).”
§ Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement > Abstract
What the sources say
- Supportedcites [11] Nieman, 2008, The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab source
Section 3.4.2, ‘Evidence for late-night salivary cortisol,’ describes loss of circadian rhythm and absence of a late-night cortisol nadir as a consistent biochemical abnormality in patients with Cushing’s syndrome. ‘Hallmark’ is a fair paraphrase of that statement. (LLM, conf=0.95)
- Not checked — no full text of the sourcecites [25] Laidlaw, 1955, Advances in the diagnosis of altered states of adrenocortical function, N Engl J Med source
- Not checked — no full text of the sourcecites [26] Doe, 1960, Diurnal variation of 17-hydroxycorticosteroids, sodium, potassium, magnesium and creatinine in normal subjects and in cases of treated adrenal insufficiency and Cushing's syndrome, J Clin Endocrinol Metab source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although overt physical features may be absent, the subtle hypercortisolism seen in MACS has been associated with adverse cardiovascular and metabolic outcomes, including hypertension, diabetes, dyslipidemia, weight gain, osteoporosis, increased frailty, and increased mortality (33, 34, 97-101).”
§ Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement > Stratification of hypercortisolism
What the sources say
- Partly supportedcites [33] Li, 2023, Determinants of muscle function and health-related quality of life in patients with endogenous hypercortisolism: a cross-sectional study, Eur J Endocrinol sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [34] Braun, 2024, Frequency of clinical signs in patients with Cushing's syndrome and mild autonomous cortisol secretion: overlap is common, Eur J Endocrinol source
- Not checked — no full text of the sourcecites [97] Elhassan, 2019, Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess: a systematic review and meta-analysis, Ann Intern Med source
- Partly supportedcites [98] Pelsma, 2023, Comorbidities in mild autonomous cortisol secretion and the effect of treatment: systematic review and meta-analysis, Eur J Endocrinol sourceExperimental — accuracy not yet measured
Pelsma et al. (2023) support most of the list: the Discussion (p. ~"Discussion") states that "the prevalence of cardiometabolic diseases was increased in patients with MACS, with the prevalence of diabetes, hypertension, and dyslipidemia being 15%-40% higher," with pooled RRs of 1.44 (diabetes), 1.24 (hypertension) and 1.23 (dyslipidemia) in the Metabolic and cardiovascular comorbidities section, and increased mortality (HR = 1.54, 95% CI 1.27-1.81) in the Mortality section; the Introduction also frames MACS as hypercortisolism without clinical signs of overt Cushing's syndrome. However, our copy contains no comorbidity outcome on weight gain/obesity or on frailty (searched: obesity, body mass index, weight gain, frailty, bone mineral density) — the only bone-related data are on vertebral/fragility fractures, where prevalence of multiple fracture types "was assessed and found to have not increased" and no pooled statistic was provided, so the osteoporosis element is at best weakly reflected. The claim also states these associations flatly, whereas the source hedges them (dyslipidemia "less solid," causality "disputed," quality of evidence low). (LLM, conf=0.78)
- Partly supportedcites [99] Dogra, 2023, High prevalence of frailty in patients with adrenal adenomas and adrenocortical hormone excess: a cross-sectional multi-centre study with prospective enrolment, Eur J Endocrinol sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Could not verifycites [100] Prete, 2022, Cardiometabolic disease burden and steroid excretion in benign adrenal tumors: a cross-sectional multicenter study, Ann Intern Med sourceExperimental — accuracy not yet measured
Our copy of Prete et al. (2022) contains only the repository metadata record — the title, full author list, journal details (Ann Intern Med 175(3):325-334), the RIS/BIBTEX citation blocks, an 'Abstract' heading with no abstract text, and a link to the manuscript PDF. No passage addresses mild autonomous cortisol secretion or any of the outcomes in the claim (hypertension, diabetes, dyslipidemia, weight gain, osteoporosis, frailty, mortality); searches with 'mild autonomous cortisol secretion cardiometabolic disease burden', 'subtle hypercortisolism adverse outcomes mortality frailty osteoporosis', 'abnormal dexamethasone suppression test', 'urinary steroid excretion ... abstract', and 'hypertension type 2 diabetes dyslipidemia obesity bone mineral density fracture mortality' returned only metadata. The decisive content is therefore absent from our copy rather than contradicted. (LLM, conf=0.72)
- Partly supportedcites [101] Deutschbein, 2022, Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study, Lancet Diabets Endocrinol sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The diagnosis of endogenous CS can be challenging due to overlap with common conditions, highly variable clinical features, and challenges in appropriately interpreting biochemical screening and diagnostic tests (11, 48-52).”
§ Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement > Diagnostic algorithm
What the sources say
- Supportedcites [11] Nieman, 2008, The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab source
Section 1.0 says that Cushing’s syndrome has a broad clinical presentation, can be challenging to diagnose in mild cases, and overlaps with common conditions. Sections 3.4 and 3.6–3.8 describe variable hypercortisolism, discordant results, assay-dependent normal ranges, and the need to interpret tests in light of patient- and test-specific caveats. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [48] Ceccato, 2025, Clinical and biochemical data for the diagnosis of endogenous hypercortisolism: the “cushingomic” approach, J Clin Endocrinol Metab source
- Supportedcites [49] Braun, 2022, Whom should we screen for Cushing syndrome? The Endocrine Society practice guideline recommendations 2008 revisited, J Clin Endocrinol Metab source
The copy’s Abstract section says diagnosis is difficult because symptoms vary and overlap with common conditions and pseudo-Cushing states. Patients and Data Acquisition also describes using multiple biochemical tests and repeating samples when results might be false positive or false negative, supporting the point about interpreting tests. (LLM, conf=0.85)
- Partly supportedcites [50] Rubinstein, 2020, Time to diagnosis in Cushing's syndrome: a meta-analysis based on 5367 patients, J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
The introduction says CS symptoms overlap with other conditions and can delay diagnosis. The Discussion describes unusual and progressive presentations and says current biochemical screening tests have significant sensitivity and specificity issues (p. 22). These passages support diagnostic difficulty, but do not specifically address challenges in interpreting screening or diagnostic test results. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [51] Klose, 2007, Factors influencing the adrenocorticotropin test: role of contemporary cortisol assays, body composition, and oral contraceptive agents, J Clin Endocrinol Metab source
- Supportedcites [52] Giraldi, 2007, Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series, J Clin Endocrinol Metab source
The introduction (p. 1) says recognizing endogenous Cushing’s syndrome remains challenging because patients may have only subtle clinical features and clinicians must consider it in people with common conditions such as obesity, depression, hypertension, and diabetes. The Discussion (pp. 4, 6) describes the difficulty of choosing and interpreting screening tests and diagnostic thresholds. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Among patients with CS, normalization of cortisol concentrations results in improvements in morbidity, mortality, and quality of life (28, 35, 109, 110).”
§ Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement > Stratification of hypercortisolism
What the sources say
- Not checked — no full text of the sourcecites [28] Puglisi, 2024, Long-term consequences of Cushing syndrome: a systematic literature review, J Clin Endocrinol Metab source
- Partly supportedcites [35] Schernthaner-Reiter, 2019, Factors predicting long-term comorbidities in patients with Cushing's syndrome in remission, Endocrine sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says remission of glucocorticoid excess often improves signs and symptoms, but comorbidities are not always reversible. The Discussion (page unavailable) notes residual impairment in quality of life, while the Introduction says cardiovascular mortality risk remains elevated decades after remission. The paper therefore does not support an unqualified claim of improvements in all three outcomes, particularly mortality. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [109] Lindsay, 2006, Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission, J Clin Endocrinol Metab source
- Partly supportedcites [110] Newell-Price, 2025, Improved clinical outcomes during long-term osilodrostat treatment of Cushing disease with normalization of late-night salivary cortisol and urinary free cortisol, J Endocr Soc sourceExperimental — accuracy not yet measured
The Discussion (page not provided) says cortisol normalization is a treatment goal intended to reduce comorbidities and mortality risk. The Results report improved cardiovascular/metabolic measures and quality of life in patients with Cushing disease whose cortisol measures were controlled. The paper does not report improved mortality, and describes mortality reduction as a potential benefit rather than an observed outcome. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
54 more claims · 18 with their cited sources checked
Create a free account to see all 96 claims and to verify the 24 references still open.
- It may state two separate claims as one. 30
- Probably not a substantial claim. 8
- The quote only partly states this claim. 2
Citations
Cites
Vale, W., Spiess, J., Rivier, C., & Rivier, J. (1981) · Science · doi:10.1126/science.6267699 · Cited by 3,965
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718
Adverse metabolic and cardiovascular consequences of circadian misalignment
Scheer, F. A. J. L., Hilton, M. F., Mantzoros, C. S., & Shea, S. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808180106 · Cited by 2,351
Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1710 · Cited by 1,769
Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk
Cohen, S., Janicki-Deverts, D., Doyle, W. J., Miller, G. E., Frank, E., Rabin, B. S., & Turner, R. B. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118355109 · Cited by 1,419
Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline
Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1818 · Cited by 1,270
Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects
WEITZMAN, E. D., FUKUSHIMA, D., NOGEIRE, C., ROFFWARG, H., GALLAGHER, T. F., & HELLMAN, L. (1971) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-33-1-14 · Cited by 1,258
Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin
Gillies, G. E., Linton, E. A., & Lowry, P. J. (1982) · Nature · doi:10.1038/299355a0 · Cited by 965
Consensus on diagnosis and management of Cushing's disease: a guideline update
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N. R., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00235-7 · Cited by 953
Self-citationFassnacht, M., Tsagarakis, S., Terzolo, M., Tabarin, A., Sahdev, A., Newell-Price, J., Pelsma, I., Marina, L., Lorenz, K., Bancos, I., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad066 · Cited by 786
Self-citation
Research works printed but not linked: 2
- Dallman, 1969, Dynamic asymmetries in the corticosteroid feedback path and distribution of tissue receptors, Am J Physiol, 216, 1221
- Kuze, 2016, The diagnostic value of late-night salivary cortisol for diagnosis of subclinical Cushing's syndrome, Endokrynol Pol, 67, 487
Cited by
Mild Autonomous ACTH Secretion: A Narrative Review of 52 Cases from the Literature
Nicoli, F., Eller-Vainicher, C., Cozzi, R. C., Chiodini, I., & Favero, V. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.08.016
Metadata
- Authors
- Hamidi, O., St-Jean, M., Lacroix, A., & Bancos, I.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Division of Endocrinology, Department of Medicine, Centre hospitalier de l’Université de Sherbrooke , Sherbrooke, QC J1H 5H3 ,
- Centre Hospitalier de l’Université de Montréal (CA)
- Mayo Clinic (US)
- Corresponding author
- Bancos, Irina
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2026-03-14
- Volume
- 111
- Issue
- 6
- Pages
- 1513-1527
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC13183435
- OpenAlex
- W7135403789
- Cited by
- 5
- References
- 136
- Citations by year
- 2026: 5
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institutes of Health
- Recordati Rare Diseases Inc
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Keywords
- Cushing's syndrome, cortisol measurement, diurnal cortisol rhythm, hypercortisolism, biochemical tests
- MeSH terms
- Circadian Rhythm, Cushing Syndrome, Humans, Hydrocortisone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. https://app.cochat.ai/papers/10.1210/clinem/dgag095
- The paper
- Hamidi, O., St-Jean, M., Lacroix, A., & Bancos, I. (2026). Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag095
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.